AI Summary of Peer-Reviewed Research
This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. See full disclosure ↓
⚠️ This article summarizes published research and is intended for informational purposes only. It does not constitute medical advice or clinical guidance.
Publication Signals show what we were able to verify about where this research was published.MODERATECore publication signals for this source were verified. Publication Signals reflect the source’s verifiable credentials, not the quality of the research.
- ✔ Peer-reviewed source
- ✔ No retraction or integrity flags
Key findings from this study
This research indicates that:
- Prenatal buprenorphine exposure demonstrated no increased risk of adverse long-term neurodevelopmental outcomes compared with methadone.
- Both medications showed comparable developmental trajectories in exposed children across follow-up assessment periods.
- Buprenorphine represents a safe pharmacological option for treating opioid use disorder during pregnancy.
Overview
A population-based cohort study compared long-term neurodevelopmental outcomes in children exposed prenatally to buprenorphine versus methadone. The research evaluated whether either medication carried differential risk for adverse neurological development when used to treat maternal opioid use disorder during pregnancy.
Methods and approach
The study employed a population-based cohort design to examine neurodevelopmental trajectories in children with in utero exposure to these medications. Comparison between exposure groups and control populations assessed outcomes over extended follow-up periods.
Results
Prenatal exposure to buprenorphine did not confer increased risk of long-term adverse neurodevelopmental outcomes relative to methadone exposure. The cohort data demonstrated comparable developmental trajectories across both medication groups, with no significant elevation in neurodevelopmental complications.
Implications
These findings provide evidence supporting buprenorphine as a pharmacologically appropriate option for opioid use disorder management during pregnancy. The comparable safety profile between buprenorphine and methadone expands clinical options while maintaining fetal and neonatal safety considerations. Results contribute to evidence-based treatment guidelines that balance maternal therapeutic needs against potential developmental risks to offspring.
Scope and limitations
This summary is based on the study abstract and available metadata. It does not include a full analysis of the complete paper, supplementary materials, or underlying datasets unless explicitly stated. Findings should be interpreted in the context of the original publication.
Disclosure
- Research title: Prenatal exposure to buprenorphine or methadone and adverse neurodevelopmental outcomes: population based cohort study
- Authors: Sabine Friedrich, Krista F Huybrechts, Loreen Straub, Sonia Hernandez-Diaz, Yanmin Zhu, Georg Hahn, Helen Mogun, Hendrée E. Jones, Hilary S Connery, Jonathan M Davis, Kathryn J Gray, Barry Lester
- Institutions: Brigham and Women's Hospital, Friends Research Institute, Harvard University, McLean Hospital, Stanford University, Tufts Medical Center, University of North Carolina at Chapel Hill, University of Washington, Women & Infants Hospital of Rhode Island
- Publication date: 2026-04-15
- DOI: https://doi.org/10.1136/bmj-2025-087321
- OpenAlex record: View
- Image credit: Photo by newarta on Pixabay (Source • License)
- Disclosure: This post was generated by Claude (Anthropic). The original authors did not write or review this post.
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.